Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency

Functional Dissection of the Epidermal Growth Factor Receptor Epitopes Targeted by Panitumumab and Cetuximab

(2015) Mareike Voigt et al.   NEOPLASIA

Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy

(2014) D E Oppenheim et al.   BRITISH JOURNAL OF CANCER

IgG1 anti-epidermal growth factor receptor antibodies induce CD8-dependent antitumor activity

(2014) Jan Kubach et al.   INTERNATIONAL JOURNAL OF CANCER

Enhancement of the Tumor Penetration of Monoclonal Antibody by Fusion of a Neuropilin-Targeting Peptide Improves the Antitumor Efficacy

(2014) T.-H. Shin et al.   MOLECULAR CANCER THERAPEUTICS

Development of a Cell-Based Assay Measuring the Activation of FcγRIIa for the Characterization of Therapeutic Monoclonal Antibodies

(2014) Minoru Tada et al.   PLoS One

Genetic Ablation of Epidermal EGFR Reveals the Dynamic Origin of Adverse Effects of Anti-EGFR Therapy

(2013) F. Mascia et al.   Science Translational Medicine

Epidermal EGFR Controls Cutaneous Host Defense and Prevents Inflammation

(2013) B. M. Lichtenberger et al.   Science Translational Medicine

Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index

(2013) L. R. Desnoyers et al.   Science Translational Medicine

GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab

(2012) C. A. Gerdes et al.   CLINICAL CANCER RESEARCH

Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases

(2012) Oran Erster et al.   JOURNAL OF CONTROLLED RELEASE

Crosstalk between Human IgG Isotypes and Murine Effector Cells

(2012) M. B. Overdijk et al.   JOURNAL OF IMMUNOLOGY

Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities

(2012) Shan Chung et al.   mAbs

Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay

(2012) Bhavin S. Parekh et al.   mAbs

Selective Photodetection and Photodynamic Therapy for Prostate Cancer through Targeting of Proteolytic Activity

(2012) M.-F. Zuluaga et al.   MOLECULAR CANCER THERAPEUTICS

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

(2012) Clara Montagut et al.   NATURE MEDICINE

Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade

(2012) S Kasper et al.   ONCOGENE

Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII)

(2011) Katja Klausz et al.   CANCER SCIENCE

Safety and Efficacy of Panitumumab Therapy After Progression With Cetuximab: Experience at Two Institutions

(2011) Muhammad Wasif Saif et al.   Clinical Colorectal Cancer

Anti-EGFR Monoclonal Antibodies for Treatment of Colorectal Cancers: Development of Cetuximab and Panitumumab

(2011) Benoit You et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin

(2010) Melarkode S. Ramakrishnan et al.   mAbs

Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment

(2009) Jaume Capdevila et al.   CANCER TREATMENT REVIEWS

The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy

(2009) Salvatore Ulisse et al.   CURRENT CANCER DRUG TARGETS

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

(2009) Tanja Schneider-Merck et al.   JOURNAL OF IMMUNOLOGY

Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities

(2008) A. Natsume et al.   CANCER RESEARCH

Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies

(2008) M. Dechant et al.   CANCER RESEARCH

Effector mechanisms of therapeutic antibodies against ErbB receptors

(2008) Matthias Peipp et al.   CURRENT OPINION IN IMMUNOLOGY

Structural and Functional Characterization of Disulfide Isoforms of the Human IgG2 Subclass

(2008) Thomas M. Dillon et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer

(2008) Amit Kumar et al.   JOURNAL OF CLINICAL ONCOLOGY

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFR Antagonists in Cancer Treatment

(2008) Fortunato Ciardiello et al.   NEW ENGLAND JOURNAL OF MEDICINE